Wagner M. Zago, Ph.D., is a distinguished neuroscientist and the Chief Scientific Officer at Prothena Corporation plc, a clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative and rare peripheral amyloid diseases. Dr. Zago holds a Ph.D. in Neuroscience from the University of São Paulo, Brazil, and has built an illustrious career in the field of neuroscience and drug development. Prior to joining Prothena, he held significant roles at major pharmaceutical companies, including Janssen Pharmaceuticals and Elan Pharmaceuticals, where he contributed to the development of therapies for Alzheimer's disease and other neurodegenerative disorders. At Prothena, Dr. Zago leads the scientific and research efforts, overseeing the company's pipeline of innovative treatments aimed at addressing unmet medical needs in neurodegenerative diseases. His leadership has been instrumental in advancing Prothena's programs, including the development of PRX002/RG7935, a potential treatment for Alzheimer's disease, and PRX004, a novel therapy for ATTR amyloidosis. Dr. Zago's expertise in protein misfolding and amyloid diseases has been pivotal in guiding Prothena's research strategy and fostering collaborations with leading academic and industry partners. His dedication to advancing scientific knowledge and translating it into meaningful therapies underscores his significant contributions to the field of neuroscience and the mission of Prothena.